Literature DB >> 31884342

RAD21 inhibited transcription of tumor suppressor MIR4697HG and led to glioma tumorigenesis.

Yuhang Mao1, Gang Shen1, Zuopeng Su1, Jiarui Du1, Fulin Xu2, Yong Yu3.   

Abstract

BACKGROUND: Studies have revealed the aberrant expression of lncRNAs is responsible for human carcinogenesis. MIR4697 host gene (MIR4697HG) is an upregulated lncRNA that promoted cell growth and metastasis in other cancers. In this study, we tested the expression of MIR4697HG in glioma cells and detected the comparatively down-regulated expression. RAD1 is an upstream regulator for MIR4697HG. This study aimed at exploring the regulatory mechanism and function of RAD1/MIR4697HG/PRR12 axis in glioma.
METHODS: We profiled the expression of MIR4697HG in glioblastoma multiforme (GBM) tissues according to GEPIA database as well as in glioma cells by qPCR. Functional experiments confirmed relevant role of MIR4697HG in regulating glioma cell proliferation and migration. We also carried out luciferase reporter assay, pull down assay and RIP assay to verify the location and interaction among the indicated RNA molecules.
RESULTS: The expression of MIR4697HG is down-regulated significantly in glioma cells due to the up-regulated expression of RAD21. MiR-766-5p was identified functioning as a sponge for MIR4697HG and is sequestered by MIR4697HG. We also found either miR-766-5p inhibitor or PRR12 knockdown rescued the function depletion caused by MIR4697HG overexpression. In all, the down-regulated expression of MIR4697HG inhibited PRR12 to suppress glioma and led to the deterioration of glioma.
CONCLUSION: RAD21-induced down-regulated expression of MIR4697HG is correlated with aggravation of glioma. The MIR4697HG/miR-766-5p/PRR12 axis predicts poor results in glioma and MIR4697HG could be considered as a promising biomarker for diagnosis and treatment of glioma.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Glioma; MIR4697HG; RAD21; ceRNA

Mesh:

Substances:

Year:  2019        PMID: 31884342     DOI: 10.1016/j.biopha.2019.109759

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  [Knockdown of long non-coding RNA MIR4697 host gene inhibits adipogenic differentiation in bone marrow mesenchymal stem cells].

Authors:  T Shuai; J Liu; Y Y Guo; C Y Jin
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-18

2.  A diagnostic and predictive lncRNA lnc-MPEG1-1 promotes the proliferation and metastasis of papillary thyroid cancer cells by occupying miR-766-5p.

Authors:  Chan Huang; Xuan Su; Da-Lei Zhou; Bo-Heng Xu; Qing Liu; Xiao Zhang; Tao Tang; Xin-Hua Yang; Zu-Lu Ye; Cai-Yun He
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-31       Impact factor: 10.183

Review 3.  Non-coding RNAs and glioblastoma: Insight into their roles in metastasis.

Authors:  Seyed Mojtaba Mousavi; Maryam Derakhshan; Fatereh Baharloii; Fatemeh Dashti; Seyed Mohammad Ali Mirazimi; Maryam Mahjoubin-Tehran; Saereh Hosseindoost; Pouya Goleij; Neda Rahimian; Michael R Hamblin; Hamed Mirzaei
Journal:  Mol Ther Oncolytics       Date:  2021-12-22       Impact factor: 7.200

4.  Insights into the Association Between QSER1 and M2 Macrophages and Remarkable Malignancy Characteristics in Hepatocellular Carcinoma.

Authors:  Min Wu; Qi-Man Shi; Sai-Li Duan; Deng-Jie Ou-Yang; Pei Chen; Biao Tu; Peng Huang
Journal:  Int J Gen Med       Date:  2022-02-18

5.  The lncRNA NEAT1/miRNA-766-5p/E2F3 Regulatory Axis Promotes Prostate Cancer Progression.

Authors:  Wenhui Zhao; Xinshu Zhu; Qiu Jin; Bo Lin; Runyuan Ji
Journal:  J Oncol       Date:  2022-02-21       Impact factor: 4.375

6.  High-Throughput Sequencing-Based Identification of Serum Exosomal Differential miRNAs in High-Grade Glioma and Intracranial Lymphoma.

Authors:  Shun Wang; Zhenkuan Xu; Chao Zhang; Rui Yu; Jun Jiang; Chengwei Wang; Chuncheng Qu
Journal:  Biomed Res Int       Date:  2020-10-07       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.